NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) --WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ:VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=36783 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.WHAT IS THIS ABOUT: On February 27, 2025, before the market opened, Viatris issued a press release announcing its fourth quarter and full year 2024 financial results. In part, the ...Full story available on Benzinga.com
Viatris is a Pennsylvania-based pharmaceutical company that researches and develops generic and biosimilar drugs for the treatment of infectious diseases.